Breaking immune tolerance for the treatment of pancreatic cancer: Phase I/II clinical experience.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.8_suppl.54
Abstract: 54 Background: Escalating Intratumoral heterogeneity resulting in xenogenization which is countered by overexpression of TGF-β. Here we report on the use of OT-101/Chemo to break immune tolerance to cure pancreatic cancer (PC). OT-101 is an… read more here.
Keywords: 101 chemo; treatment; immune tolerance; chemo ... See more keywords